Written by the Nuvirox Research Team
- The only human joint-pain trial for cissus (n=29) had no placebo group, so its positive result can't rule out placebo effect.
- A 2017 systematic review of cissus RCTs found solid support for bone-fracture healing, not joint pain specifically.
- Mechanistic (lab) anti-inflammatory evidence is stronger than the clinical joint-pain evidence.
Short answer: cissus quadrangularis has one small, uncontrolled human study suggesting it eases exercise-related joint pain — a real signal, but not proof. The plant has a longer, better-supported track record for helping bone fractures heal, which is a related but different claim than relieving arthritis-type joint pain.
What is Cissus quadrangularis, and why would it affect joints?
Short mechanism: it's a traditional Ayurvedic plant with anti-inflammatory and antioxidant compounds that plausibly reduce joint inflammation, though the human evidence specific to joint pain is thin. Cissus quadrangularis is a succulent, square-stemmed vine used for centuries in Ayurvedic and African traditional medicine, primarily to speed bone fracture healing. Its extracts contain ketosterones, triterpenoids, and flavonoids that have shown anti-inflammatory activity in lab studies — including inhibition of COX and 5-LOX enzymes, the same inflammatory pathways targeted by NSAIDs like ibuprofen. That mechanistic story is why supplement companies have extended cissus from "bone healing" into "joint pain," even though those are related but distinct claims.
Does cissus quadrangularis actually reduce joint pain in humans?
The honest answer: there is exactly one human trial testing this directly, and it wasn't placebo-controlled. A 2013 pilot study out of the University of Memphis gave 3,200 mg of cissus daily to 29 exercise-trained men with chronic, exercise-related joint pain for eight weeks. Everyone in the study received the active supplement — there was no placebo group to compare against. Pain scores, measured with the WOMAC osteoarthritis index, dropped over the eight weeks. That's a real, measured result, but without a control group it's impossible to separate the supplement's effect from a placebo response, natural fluctuation in exercise-related soreness, or the men simply training a bit differently once they knew they were being watched.
Why does cissus keep showing up in "joint" formulas if the joint evidence is thin?
Short answer: momentum from its bone-healing reputation, plus a real (if narrow) anti-inflammatory mechanism, make it an easy ingredient to market for joints even though the clinical trial base hasn't caught up. Supplement formulation tends to borrow evidence across related but distinct claims — "supports bone" and "supports joints" sound close enough that ingredients validated for one often get marketed for the other. Cissus's fracture-healing data is genuinely solid; its joint-pain data is a single small pilot. Knowing which claim an ingredient's evidence actually supports is useful before assuming a product's full ingredient list is equally well-tested across every listed benefit.
What human studies actually show
Bloomer et al., 2013 (Physician and Sportsmedicine). Design: 8-week, open-label (no placebo), single-arm. n=29 exercise-trained men, ages 20–46, with chronic exercise-related joint pain. Dose: 3,200 mg/day. Finding: WOMAC pain scores improved significantly from baseline to week 8, alongside favorable shifts in some inflammatory blood markers. Because there was no comparison group, the study can't rule out placebo effect, regression to the mean, or behavior change during the study.
Sawangjit et al., 2017 (Phytotherapy Research), systematic review and meta-analysis. This review pooled all available randomized controlled trials of cissus across every condition it's been tested for — not just joints. It found meaningful support for cissus speeding bone fracture healing, and for combination products modestly aiding weight loss, but it did not identify enough controlled joint-pain trials to run a pooled analysis on that outcome specifically. In plain terms: the rigorous RCT evidence base for cissus is real, but it's concentrated in bone healing and metabolic outcomes, not joint pain.
Honest counterweight. The single joint-pain-specific human study lacked a placebo arm, had a small, all-male, exercise-trained sample, and measured a self-report pain scale that's known to be responsive to expectation. That's a meaningfully weaker evidence base than several other joint ingredients (glucosamine, chondroitin, curcumin) that have been tested in placebo-controlled trials with hundreds of participants.
What cissus quadrangularis won't do
Cissus has no evidence of reversing cartilage loss or slowing structural joint damage — its studied use case is fracture healing and, in one small trial, subjective pain during heavy exercise. If your joint pain is accompanied by significant swelling, warmth, joint locking, or pain that wakes you at night, those are signs worth having evaluated by a doctor rather than managed with a supplement whose evidence base is a single 29-person open-label study. If you're weighing cissus against better-studied options, glucosamine and chondroitin combination therapy and collagen for joint pain both have larger placebo-controlled trial bases to compare against.
Dosing and what to expect
The one human joint-pain trial used 3,200 mg/day split across the day, for eight weeks before assessing results. Other cissus research (mostly bone- and metabolism-focused) has used doses from 300 mg to over 1,000 mg/day. There's no dose-response data specific to joint pain, so higher doses aren't established as more effective — they're just what one small study happened to use. For context on how a genuinely well-designed positive trial looks, the GLA (borage oil) research in rheumatoid arthritis is a useful comparison point.
Frequently asked questions
Is cissus quadrangularis safe to take with diabetes medication?
Cissus has been reported to lower blood sugar in some studies, which means it could theoretically add to the effect of diabetes medications. If you take insulin or a sulfonylurea, talk to your doctor before adding it.
How is cissus different from glucosamine or chondroitin for joints?
Glucosamine and chondroitin are structural cartilage components with large placebo-controlled trial programs behind them (imperfect results, but real data). Cissus's clinical evidence for joints is a single small pilot study; its stronger evidence is for bone fracture healing.
How long before cissus might help joint pain, based on the research?
The only human joint-pain study ran for 8 weeks before measuring results, so that's the honest timeline to expect any signal — if there is one.
Does cissus interact with any medications?
Beyond the diabetes medication caution, cissus has limited drug-interaction research. Anyone on prescription medication should mention it to a pharmacist or doctor before starting.
Is cissus quadrangularis the same thing as collagen or glucosamine?
No. Collagen and glucosamine are structural building blocks the body uses for cartilage and connective tissue. Cissus is a plant extract studied mainly for anti-inflammatory activity and bone-healing support, a different category of mechanism entirely.
From Nuvirox
Why we formulated Joint+ Restore
Joint+ Restore is currently being reformulated, so rather than list ingredients that may change, here is the honest version: it is built around the same philosophy this article takes toward the evidence — support ingredients chosen for plausible, human-trial-backed mechanisms, dosed in ranges that show up in the research, not proprietary-blend guesswork. It is not a replacement for medical care, and it will not undo structural joint damage. It is meant to be one reasonable piece of a broader approach to joint health alongside movement, weight management, and (where relevant) your doctor’s guidance.
It comes with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about Joint+ Restore →The bottom line
Cissus quadrangularis has a real, if narrow, human evidence base: solid support for bone fracture healing, and one small, uncontrolled pilot study suggesting it might ease exercise-related joint pain. That's a plausible lead, not a proven joint-pain treatment. If you try it, an 8-week trial at the studied dose is a reasonable way to see whether it does anything for you personally, alongside — not instead of — the basics: appropriate loading, mobility work, and medical evaluation for pain that doesn't fit an exercise-soreness pattern.
References
- Bloomer RJ, Farney TM, McCarthy CG, Lee SR. Cissus quadrangularis reduces joint pain in exercise-trained men: a pilot study. Phys Sportsmed. 2013;41(3):29-35. PMID: 24113700.
- Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2017;31(4):555-567. PMID: 28165166.
- Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytother Res. 2013;27(8):1107-1114. PMID: 22976133.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.